This article has been updated from a version posted Sept. 19 to include comments from Illumina officials.
Illumina's acquisition of BlueGnome, announced last week, will broaden the San Diego firm's opportunities in molecular diagnostics, according to its top executive.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
